Intraoperative neuromonitoring market size was valued at $3,036 million in 2015, and is expected to reach $4,900 million by 2022, growing at a CAGR of 7.0% from 2016 to 2022.

Portland, OR -- (SBWire) -- 07/12/2017 --Intraoperative Neuromonitoring (IONM) Market was valued at $3,036 million in 2015, and is projected to reach $4,900 million by 2022, growing at a CAGR of 7% from 2016 to 2022, according to a new report published by Allied Market Research.

Early buyers will receive 20% customization on this report!

IONM systems segment accounted for nearly half of the total market in 2015. IONM systems help in the identification of neural structures during a surgery. This helps the surgeons to prevent any damage to the nervous system, which may be caused during the surgery and reduce post-operative complications. Thus, IONM systems identify any progressive threat to the nervous system and alert the surgeon prior to reaching the patients threshold for injury.

For Sample PDF – Click Here!!!

Ageing population, increase in prevalence of chronic disorders, applications of IONM in different surgeries, and risk management through IONM during complex surgeries drive the market. However, low awareness of IONM in developing nations and lack of skilled professionals restrain the market growth. Increase in medical tourism and growth opportunities in the emerging economies of the Asia-Pacific and LAMEA regions are expected to provide several opportunities for key players.

Outsourced IONM monitoring is growing at a fast pace due to its benefits over insourced monitoring. Now-a-days, hospitals do not prefer insourced monitoring as they have to appoint a full-time employee with the required skill set and they cannot offer the training standardization required to improve the quality of service. Thus, outsourced monitoring is in demand among hospitals and ASCs, and the market gradually shifts toward outsourced monitoring services.

Do Purchase Inquiry@ https://www.alliedmarketresearch.com/purchase-enquiry/1920

IONM is most commonly used during spinal and neurosurgery. However, there is an increase in the use of IONM for orthopedic as well as ENT surgeries as these surgeries pose a potential risk to the neural structures and require a technique, which protects nerves (and other related structures) during the procedure.

Key Findings of Intraoperative Neuromonitoring Market

- Based on applications, spinal surgery segment accounted for one-third of the total market in 2015. However, orthopedic surgery is the fastest growing application of IONM (which is expected to grow with a CAGR of 7.4% from 2016 to 2022)

- Electromyography (EMG) modality accounted for more than one-fourth of the global market in 2015.

- IONM services segment is expected to grow at a high CAGR of 10.0% during the forecast period, due to an increase in the demand for IONM service providers.

- Hospitals accounted for nearly three-fifths of the total market in 2015.

- Asia-Pacific is expected grow at a high CAGR of 8.2%, owing to the presence of ample growth opportunities in terms of unmet medical needs for IONM services in the region.

North America accounted for majority of the share (more than two-fifths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of a large number of hospitals, and increase in number of surgeries in the region. In addition, awareness among people for IONM is anticipated to provide new growth opportunities for the key players in this market. In addition, rise in geriatric population, increase in incidence of spinal deformities, spinal stenosis, disc compression, and other chronic disorders drive the IONM market in Europe.

Get Sample TOC@ https://www.alliedmarketresearch.com/request-toc-and-sample/1920

The major companies profiled in the report include Medtronic plc, NuVasive, Inc., Computational Diagnostics, Inc., SpecialtyCare, Natus Medical Incorporated., IntraNerve, LLC, inomed Medizintechnik GmbH, AccurateMonitoring LLC, Nihon Kohden Corporation, and Moberg Research, Inc.